SETD7: A Potential Drug Target and Biomarker for ALS (G80854)

Target Name: SETD7

NCBI ID: G80854

SETD7

SETD7: A Potential Drug Target and Biomarker for ALS

Amyloid-associated protein (AAP) is a protein that is found in the brains of individuals with Alzheimer's disease (ALS), as well as in other neurodegenerative disorders. The misfolded form of AAP, known as amyloid tangles, is thought to contribute to the development and progression of these disorders.SETD7 is a gene that has been identified as a potential drug target and biomarker for ALS. In this article, we will explore the biology of SETD7 and its potential as a drug target for ALS.

The Importance of SETD7 in ALS

SETD7 is a gene that encodes a protein known as SETD7-like, which is also known as H3-K4-HMTase. This protein is involved in the regulation of gene expression and is thought to play a role in the development and progression of ALS.

The misfolded form of AAP, known as amyloid tangles, is a hallmark of ALS. These tangles are thought to contribute to the neurotoxicity and inflammation that occurs in this disease.SETD7 has been shown to be expressed in the brains of individuals with ALS and has been shown to interact with the protein huntingtin.

The Potential Role of SETD7 as a Drug Target

SETD7 has been identified as a potential drug target for ALS due to its involvement in the regulation of gene expression and its expression in the brains of individuals with this disease. By targeting SETD7, researchers hope to reduce the production of amyloid tangles and improve the overall neurotoxicity of ALS.

One approach to targeting SETD7 is to use small molecules that can modulate its activity. Researchers have identified a number of small molecules that have been shown to interact with SETD7 and have the potential to be used as drug candidates for ALS.

The Potential Role of SETD7 as a Biomarker

SETD7 has also been identified as a potential biomarker for ALS. The misfolded form of AAP, known as amyloid tangles, is a hallmark of this disease and is thought to contribute to the neurotoxicity and inflammation that occurs in ALS.

By studying the expression and distribution of SETD7 in the brains of individuals with ALS, researchers hope to gain insights into the role of this gene in the development and progression of this disease. This information could be used to develop new diagnostic tests for ALS and to identify potential targets for new treatments.

Conclusion

SETD7 is a gene that has been identified as a potential drug target and biomarker for ALS. Its involvement in the regulation of gene expression and its expression in the brains of individuals with this disease make it an attractive target for researchers. While more research is needed to fully understand the role of SETD7 in ALS, its potential as a drug target and biomarker is an exciting area of study.

Protein Name: SET Domain Containing 7, Histone Lysine Methyltransferase

Functions: Histone methyltransferase that specifically monomethylates 'Lys-4' of histone H3 (PubMed:11779497, PubMed:11850410, PubMed:12588998, PubMed:12540855, PubMed:16141209). H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation (PubMed:12588998, PubMed:12540855, PubMed:16141209). Plays a central role in the transcriptional activation of genes such as collagenase or insulin (PubMed:16141209, PubMed:12588998). Recruited by IPF1/PDX-1 to the insulin promoter, leading to activate transcription (PubMed:16141209). Has also methyltransferase activity toward non-histone proteins such as CGAS, p53/TP53, TAF10, and possibly TAF7 by recognizing and binding the [KR]-[STA]-K in substrate proteins (PubMed:15099517, PubMed:35210392, PubMed:15525938, PubMed:16415881). Monomethylates 'Lys-189' of TAF10, leading to increase the affinity of TAF10 for RNA polymerase II (PubMed:15099517, PubMed:16415881). Monomethylates 'Lys-372' of p53/TP53, stabilizing p53/TP53 and increasing p53/TP53-mediated transcriptional activation (PubMed:17108971, PubMed:15525938, PubMed:16415881). Monomethylates 'Lys-491' of CGAS, promoting interaction between SGF29 and CGAS (By similarity)

The "SETD7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SETD7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets